PMC:7796052 / 108-939 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"14","span":{"begin":268,"end":278},"obj":"Gene"},{"id":"15","span":{"begin":430,"end":440},"obj":"Gene"},{"id":"16","span":{"begin":587,"end":597},"obj":"Gene"},{"id":"17","span":{"begin":697,"end":708},"obj":"Gene"},{"id":"18","span":{"begin":332,"end":340},"obj":"Species"},{"id":"19","span":{"begin":454,"end":464},"obj":"Chemical"},{"id":"20","span":{"begin":568,"end":578},"obj":"Chemical"},{"id":"21","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"22","span":{"begin":353,"end":361},"obj":"Disease"},{"id":"23","span":{"begin":809,"end":817},"obj":"Disease"}],"attributes":[{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"Gene:3827"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"Gene:3827"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"Gene:3827"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"Gene:624"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"Tax:9606"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D020849"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:D020849"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"MESH:C000657245"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"MESH:C000657245"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Covid-19 urges a deeper understanding of the underlying molecular mechanisms involved in illness progression to provide a prompt therapeutical response with an adequate use of available drugs, including drug repurposing. Recently, it was suggested that a dysregulated bradykinin signaling can trigger the cytokine storm observed in patients with severe Covid-19. In the scope of a drug repurposing campaign undertaken to identify bradykinin antagonists, raloxifene was identified as prospective compound in a virtual screening process. The pharmacodynamics profile of raloxifene towards bradykinin receptors is reported in the present work, showing a weak selective partial agonist profile at the B2 receptor. In view of this new profile, its possible use as a therapeutical agent for the treatment of severe Covid-19 is discussed."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":305,"end":319},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Covid-19 urges a deeper understanding of the underlying molecular mechanisms involved in illness progression to provide a prompt therapeutical response with an adequate use of available drugs, including drug repurposing. Recently, it was suggested that a dysregulated bradykinin signaling can trigger the cytokine storm observed in patients with severe Covid-19. In the scope of a drug repurposing campaign undertaken to identify bradykinin antagonists, raloxifene was identified as prospective compound in a virtual screening process. The pharmacodynamics profile of raloxifene towards bradykinin receptors is reported in the present work, showing a weak selective partial agonist profile at the B2 receptor. In view of this new profile, its possible use as a therapeutical agent for the treatment of severe Covid-19 is discussed."}

{"project":"LitCovid-sentences","denotations":[{"id":"T3","span":{"begin":0,"end":220},"obj":"Sentence"},{"id":"T4","span":{"begin":221,"end":362},"obj":"Sentence"},{"id":"T5","span":{"begin":363,"end":535},"obj":"Sentence"},{"id":"T6","span":{"begin":536,"end":709},"obj":"Sentence"},{"id":"T7","span":{"begin":710,"end":831},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Covid-19 urges a deeper understanding of the underlying molecular mechanisms involved in illness progression to provide a prompt therapeutical response with an adequate use of available drugs, including drug repurposing. Recently, it was suggested that a dysregulated bradykinin signaling can trigger the cytokine storm observed in patients with severe Covid-19. In the scope of a drug repurposing campaign undertaken to identify bradykinin antagonists, raloxifene was identified as prospective compound in a virtual screening process. The pharmacodynamics profile of raloxifene towards bradykinin receptors is reported in the present work, showing a weak selective partial agonist profile at the B2 receptor. In view of this new profile, its possible use as a therapeutical agent for the treatment of severe Covid-19 is discussed."}